Escin
Small molecule
Escin is one of 21 small molecule programs targeting COVID-19. It is currently in development.
1
Indications
3
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
Biaxin
AbbViePreclinical
Aldactone
PfizerPreclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Piperacillin/tazobactam
PfizerPreclinical
Calcium
Eli LillyPreclinical
Olokizumab
UCBPreclinical
Aprotinin
BayerPreclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Antithrombin-III
OctapharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Escin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- OOman Medical Speciality Board